Small Cap Feast

11th August 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
No joiners today
Off The Menu:
No leavers today.

What’s Cooking In The IPO Kitchen?

Unigel Group, intends to join the Aquis Growth Market. Unigel Group is a pioneer in the field of thixotropic gels for the fibre optic cable industry. The Company is also a supplier of laminated steel tapes to the fibre optic cable industry in the US. Thixotropic gels and laminated steel tapes are essential components to the rapidly growing global fibre optic cable market. The Group exports to over 40 countries and is a key supplier to almost every leading fibre optic cable manufacturer worldwide and is the industry’s only organisation with multiple manufacturing facilities spread across 3 continents. The Company acts as the holding company for its wholly-owned operating subsidiary, Unitape Limited and its 60% owned operating subsidiary, Unigel (UK) Limited. Delayed, timing TBC.

Georgina Energy, an early-stage resource company with a strategy of actively pursuing the exploration, commercial development and monetisation of helium, hydrogen and hydrocarbon interests located in the Amadeus and Officer Basins in Northern and Western Australia intends to join AIM. Georgina Energy has two principal onshore interests. The first, the Mount Winter Prospect is located in the Amadeus Basin in Northern Australia, which the Company has a right to earn an initial 75% interest. The second interest, the Hussar Prospect is 100% owned by the Company and is located in the Officer Basin in Western Australia. Expected late September.

Breakfast Buffet

C4X Discovery 24.6p £56.4m (C4XD.L)

The drug discovery company announces a proposed placing of shares with institutional investors to raise up to £5.7m in aggregate before expenses at the issue price of 25 pence per ordinary share. The Company intends to use the net proceeds to: strengthen the balance sheet as partnering discussions progress; continue to develop its portfolio of early-stage, high-value small molecule programmes; and continue to apply C4XD’s technologies to validate the next generation of commercially attractive targets and programmes.

CheckiT 27.5p £29.7m (CKT.L)

The intelligent operations platform for the deskless worker, provides an unaudited trading update for the six months ended 31 July 2022 (H1 FY23). Total group revenue of £5.4m, a decrease of 31% (2021: £7.9m). Recurring Revenue accounted for 82% of total revenue (H1 FY23: 39%), demonstrating Checkit’s transformation into a subscription business. However, additional bookings growth has been flat year-over-tear, reflecting the impact of market conditions on pipeline progression.

Eight Capital Partners 0.025p £0.4m (AQSE:ECP)

The financial services operating company, announces that Mr David Bull is stepping down from the Board as Chief Executive Officer. He joined ECP as a Non-executive Director in June of last year and was appointed CEO in September. The Board is in the process of appointing a new Chief Executive Officer. Additionally, Mr Luciano Maranzana has been appointed as a Non-executive Director. He joins ECP from Negentropy Capital Partners Italia, a London-based alternative investment management and advisory company.

Empresaria 61.5p £30.7m (EMR.L)

The global specialist staffing group, announces its unaudited interim results for the six months ended 30 June 2022. Revenue of £129.8m remained unchanged vs 1H 2021. Thanks to 15% increase in the net fee income, operating profit increased by 41% to £4.5m (2021: £2.7m). Despite the macroeconomic uncertainties, the company is optimistic about the year ahead as the demand for talent is strong. Management expects profits for the full year to be in line with market expectations.

Ironveld 0.3p £8.8m (IRON.L)

The exploration and development company announces that, following the completion of the recent placing of £4.5m, its team of specialist contractors has commenced work at the FCF Smelter site in Rustenburg, South Africa. The focus in the initial weeks will be site clean-up, security and checks. This will be followed with refurbishment and upgrades across the facility over a period of 6 to 9 months, in order to bring the first of the three furnaces to commence production.

Jaywing 10p £9.3m (JWNG.L)

The marketing and data science business specialising in integrated marketing and risk and data consulting, announces an unaudited trading update for the 12 months to 31 March 2022. Net revenue for the year is expected to increase 16% to £23.3m (2021: £20.2m) and adjusted EBITDA to be broadly in line with market expectations. The company is in discussions with the shareholders of Midisi, regarding its potential acquisition of Midisi. Midisi owns the intellectual property rights for the “Decision” software which Jaywing currently sells under a licence agreement.

Marks Electrical 72p £75.6m (MRK.L)

The online electrical retailer provides a trading update for the four months ended 31 July 2022, ahead of the AGM to be held today at 11:00 a.m. Revenue grew 13.7% to £27.7m (4m FY22 £24.3m), due to market share gains of both Major Domestic Appliances and Consumer Electrics. Given a robust balance sheet and strong cash position, the Board is proposing the final dividend of 0.67p per share, subject to shareholder approval at today’s AGM.

Mirriad Advertising 7.75p £21.6m (MIRI.L)

The in-content advertising company announces the unaudited interim results for the six months ended 30 June 2022. Revenue was £577k, down by 48% (H1 2021: £1.1m). Revenue grew in the US by 57% to £418k, while China revenue declined 85% to £120k. Operating loss was £8.5m (H1 2021: loss of £5.9m). Cash at the end of the period was £17.7m (30 June 2021: £29.8m). As previously guided, the company expects higher revenues towards the year end. Meanwhile, the cost control programme is underway to deliver a total of £2.5m annualised savings, with vast majority to be achieved in 2023.

MJ Hudson Group 28.3p £48.2m (MJH.L)

The end-to-end solutions provider to the US asset management industry, announces that it has raised £9m (before expenses) through the issuance of 30m Placing Shares at the Issue Price. The company has also raised £0.22m (before expenses) through the subscription of 742,463 Retail Offer Shares under Retail Offer following the closing of the offer on 10 August 2022. According to the RNS dated 10 August 2020, the Retail Offer Price of 30 pence per share represents a 4% discount to the closing mid-market price on 9 August 2022.

Roquefort Therapeutics* 8.5p £6.1m (ROQ.L)

The biotech company focused on early-stage opportunities, provide an update on the progress of its proprietary Midkine (MDK) antisense oligonucleotide pre-clinical drug development program, on its patent portfolio and on the Oncogeni transaction. The in vitro experiments have been completed with its proprietary oligonucleotides, successfully reducing high MDK levels in cancer cells by generating a truncated form of the MDK protein. The switch to the truncated MDK correlated with the >90% efficacy at the mRNA level previously reported. The Company has recently updated its filed patent in Australia and has also filed a UK patent to protect the composition of the truncated MDK, mRNAs and antisense oligonucleotides. The company is working on publishing a prospectus, completing the acquisition of the entire issued capital of Oncogeni.

11 August 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram